#Spain #Barcelona #Neurodegenerative Diseases #Alzheimer's Research #ADPD Conference

Call for Abstracts at AD/PD™ 2027

The AD/PD™ 2027 conference, organized by the Kenes Group, is set to take place from March 16-20, 2027, in Barcelona, Spain. This internationally recognized event focuses on advancing our understanding and treatment of neurodegenerative diseases, particularly Alzheimer's and Parkinson's. The conference aims to bring together researchers, clinicians, and industry leaders to discuss breakthrough scientific findings.

Conference Overview

AD/PD™ has a rich history, established in 1985, and has since been a crucial platform for sharing knowledge in the fields of Alzheimer’s, Parkinson’s, and related disorders. The upcoming conference will host both in-person and online participants, ensuring accessibility for a global audience.

With an estimated attendance of over 6,300 delegates and a goal of attracting more than 3,000 abstract submissions, AD/PD™ 2027 promises to be a significant milestone in the field. Participants will have the opportunity to present their cutting-edge research across 12 distinct scientific themes, which range from fundamental mechanisms and biomarker discoveries to clinical trials and emerging therapeutic strategies.

Abstract Submission Details

Researchers are invited to submit original scientific abstracts for consideration until the deadline of September 1, 2026. The abstracts will be peer-reviewed and, if accepted, included in the official conference materials. Detailed guidelines for abstract submissions can be found on the official conference portal, encouraging an array of innovative contributions to the discussion.

The 12 topics under consideration include:

• - β-amyloid diseases
• - Tauopathies
• - α-synucleinopathies
• - TDP-43 and other related diseases
• - Vascular and prion diseases
• - Demyelinating diseases and psychiatric symptoms in neurodegenerative contexts
• - Patient care and support
• - Viral infections affecting neurodegenerative diseases

This format not only facilitates a comprehensive exploration of current research but also allows networking opportunities among peers and mentors. Educational sessions and late-breaking research presentations will further enhance the sharing of knowledge.

Significance of AD/PD™

Dr. Abraham Fisher, Co-founder and President of AD/PD™, emphasizes the conference's unique position in the scientific community, stating, “What sets AD/PD™ apart is our comprehensive focus across the spectrum of neurodegenerative diseases.” The event aims to foster critical discussions, acting as a bridge between groundbreaking science and patient care, which is vital for translating research findings into effective diagnostic tools and therapies.

As AD/PD™ continues to grow and adapt to the evolving landscape of neurodegenerative diseases, it remains committed to the collaboration and engagement of researchers worldwide. In recent years, advancements in technology such as AI and precision medicine have been critical in shaping research strategies and therapeutic approaches.

Conclusion

The AD/PD™ 2027 conference represents an exceptional opportunity for the scientific community to address the challenges presented by neurodegenerative diseases. By submitting abstracts, researchers play an integral role in advancing the field and addressing the needs of patients living with Alzheimer’s and Parkinson’s.

For those looking to make a significant impact, this is a chance not to be missed. Don’t forget to visit the official conference website for more information, abstract submission guidelines, and updates leading up to this important event.